Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AQS | TSXV | CAD | Delayed | |
AQS | CBOE Canada | CAD | Real-time |
For the nine months ended 30 September 2021, Aequus Pharmaceuticals Inc revenues increased 7% to C$1.9M. Net loss increased 68% to C$1.5M. Revenues reflect Promotional services increase of 2% to C$1.8M. Higher net loss reflects Sales and marketing - Balancing value increase of 75% to C$1.2M (expense), Research and Development Expense - Balan increase from C$2K to C$243K (expense), Accretion expense increase from C$43K to C$181K (expense).
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 0.71 | 0.65 | 0.49 | 0.85 |
Gross Profit | 0.7 | 0.65 | 0.49 | |
Operating Income | -0.39 | -0.48 | -0.62 | -0.16 |
Net Income | -0.38 | -0.48 | -0.62 | -0.17 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 4.61 | 4.84 | 4.48 | 3.13 |
Total Liabilities | 2.52 | 2.41 | 2.45 | 2.56 |
Total Equity | 2.09 | 2.43 | 2.03 | 0.57 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -0.7 | -0.52 | -0.03 | -0.8 |
Cash From Investing Activities | -0.56 | -0.05 | -0.04 | -0.01 |
Cash From Financing Activities | 2.43 | 2.47 | 1.68 | 2.05 |
Net Change in Cash | 1.17 | 1.91 | 1.62 | 1.23 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review